Skip to main content

Table 3 Tumor response

From: A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound

Author, date Tumor response Complete response Partial response Stable disease Progressive disease
Imaging evaluation method Parameter evaluated Result #pt
Xiong, 2001 [53] US hyperechogenicity 21     
Xu, 2003 [54] US hypovascularity 12     
Yuan, 2003 [55] CT, US, CDFI N/A 36 8 28 0 4
Gu, 2004 [21] CDFI N/A N/A     
Li, 2004 [22] CT, US,CDFI, pathological analysis only in the effective reduction in tumor size, hyperechogenicity, blood flow decrease/disappearance 9     
Wu, 2005 [32] CT or MRI tumor reduction rate (range 20–70%) 8     
Xie, 2008 [56] US hyperchogenicity 15     
Xiong, 2009 [44] CT or MRI absence of perfusion 64     
Zhao, 2010 [45] CT RECIST 32 2 15 15 5
Orsi, 2010 [57] PET/CT, CT or MRI focal uptake of FDG, low attenuation at the ablation site without contrast enhancement at the edges 5     
Wang, 2011 [33] CT decreased enhancement 35 0 7 28 5
Sung, 2011 [35] MRI stack model (unenhanced area) 46     
Orgera, 2011 [58] PET/CT or MRI, US, CT lack of contrast and enhancement of metabolic activity 3     
Li, 2012 [59] US, CT hyperechogenicity, and hypovascularity(US), tumor necrosis and reduction (CT) 18     
Gao, 2013 [60] CT or MRI decrease or disappearance of blood supply in target region and circular enhancement in tumor periphery 30 0 5 25 9
Anzidei, 2014 [24] CT and MRI changes in density and intensity, contrast enhancement, non perfused volume (at least 60%) 6     
Sofuni, 2014 [61] CT WHO criteria 26 0 4 22 4
Marinova, 2016a [23] US lack of contrast enhancement 13     
Li YJ, 2016 [34] MRI, CT, US RECIST 11 0 7 4 5
Li X, 2016 [49] CT RECIST 16 1 15 N/A N/A
Strunk, 2016 [62] US, CT, MRI tumor ablation rate (NPV/total volume) 8     
Lv, 2016 [48] CT RECIST 18 0 10 8 0
Marinova, 2016b [36] CT and MRI tumor volume reduction N/A     
  1. FDG flurodeoxyglucose, NPV non perfused volume, CDFI color doppler flow imaging, RECIST response evaluation criteria in solid tumors